Biodegradable Copolymer Joint Depot for Synovial Drug Retention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering pharmaceutically active principles to synovial and joint tissues in mammals are inadequate in retaining the drug in the synovial area for extended periods and lack the ability to modulate the release rate of the drug over time, while also failing to target the active principles directly to these tissues effectively.
Innovation Solution
A biodegradable drug delivery composition comprising a triblock and diblock copolymer, formulated with specific repeat units and ratios, is administered to joints, where mechanical challenges within the joint cause morselization into smaller pieces, allowing prolonged retention and targeted delivery of pharmaceutically active principles to synovial tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional drug delivery methods are used to deliver pharmaceutically active principles to synovial tissues, then the drug can be administered to joints, but the drug is not retained in the synovial area for extended periods and releases too quickly
Solution Approach 1:
The polymer matrix is segmented into a triblock copolymer structure with distinct functional regions: hydrophobic polyester blocks that provide structural integrity and controlled degradation, and hydrophilic polyethylene glycol (PEG) blocks that provide drug loading capacity and modulate release. This segmentation allows independent optimization of retention and release characteristics.
Solution Approach 2:
The patent utilizes parameter changes in the polymer composition, specifically varying the ratio of polyester to PEG blocks and controlling the molecular weight and architecture of the copolymer. By adjusting these parameters, the degradation rate and drug release profile are modulated to achieve prolonged retention while controlling release speed through the biodegradation process.
2Reliability
If conventional delivery methods are used, then drugs can be administered to joints, but they fail to target active principles directly to synovial tissues effectively
Solution Approach 1:
The triblock copolymer exhibits local quality differentiation where the hydrophobic polyester segments provide structural stability and localized drug reservoir, while the hydrophilic PEG segments provide targeted interaction with synovial tissue components. This local quality variation enables selective targeting to synovial tissues without requiring complex external delivery systems.
3Duration of action of moving object
If the drug delivery composition is designed for prolonged retention, then the drug can be retained longer in the synovial area, but the release rate cannot be modulated over time
Solution Approach 1:
The polymer matrix provides dynamic release characteristics where the degradation rate can be modulated over time through the biodegradation process. The hydrolysis of ester bonds in the polyester blocks progresses at variable rates, enabling the system to transition from rapid initial release to sustained prolonged release, adapting the release profile to different therapeutic needs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves prolonged retention and controlled release of pharmaceutically active principles in synovial tissues, enhancing treatment efficacy by maintaining high drug concentrations in the synovial area and reducing systemic exposure.
Implementation Method 1
comprising a biodegradable triblock copolymer having a polyester and a polyethylene glycol and a biodegradable diblock copolymer having a polyester and an end-capped polyethylene glycol
Data Source
AI summary
A method of targeting to the synovial tissue biodegradable drug delivery compositions or morselizing biodegradable drug delivery compositions are described. The biodegradable drug composition comprises a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as at least one pharmaceutically active principle is disclosed.